Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

For Theravance, A Big Year Gets Off To A Strong Start

Executive Summary

Theravance could soon have its first substantial revenue generator on the market, the COPD therapy Breo Ellipta partnered with GlaxoSmithKline. The launch of Breo is just one of several catalysts expected to unfold for the biotech in 2013.

You may also be interested in...



Roche’s Kadcyla, Bayer’s Xofigo Head Latest Positive Opinions In Europe

GSK’s once-daily combination inhaler Relvar Ellipta along with J&J’s diabetes therapy Invokana, Novo Nordisk’s hemophilia therapy NovoEight and Gilead HIV therapy Vitekta complete the list of six new medicines recommended for approval by the CHMP, Europe’s top scientific advisory panel.

GSK’s Breo Ellipta Approved With COPD Airflow Obstruction, Exacerbation Claims

Once-daily dosing provides a convenience advantage over the other inhaled corticosteroid/long-acting beta-agonist combination products on the COPD market: GlaxoSmithKline’s own Advair and AstraZeneca’s Symbicort.

Theravance To Split Into A Royalty Play and An R&D Company

With a pair of PDUFA dates this year, Theravance is thinking ahead how to pass potential royalties to investors while continuing to fund its pipeline. The biopharma said it would separate into two public companies: a royalty play to return cash to shareholders and an R&D pipeline story.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS055287

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel